Implementation of a Joint Pulmonologist and ENT Consultation in the Care Pathway of Patients Suffering From Asthma and Chronic Rhinosinusitis With Nasal Polyposis: Effectiveness Compared With Consultations by Specialty (CON-PO Study).

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Aug 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to care for people who have both asthma and a condition called chronic rhinosinusitis with nasal polyps (CRSwNP), which affects the sinuses and nose. Since asthma affects the lungs and CRSwNP affects the upper airways, but both are connected and often happen together, the researchers want to see if having a joint appointment with both a lung doctor (pulmonologist) and an ear, nose, and throat (ENT) specialist can help patients better manage their symptoms. They hope this combined approach will reduce the need for oral corticosteroids (a type of medicine used to control inflammation) over the following year and improve overall health and quality of life.

Adults 18 years and older who have both asthma and CRSwNP, and whose symptoms are not well controlled, may be eligible for this study. Participants should have used corticosteroids in the past year to treat their symptoms. During the study, some patients will have joint visits with both specialists at the same time, while others will continue with separate visits as usual. Researchers will compare how these two groups do over time, looking at things like asthma flare-ups, sinus issues, symptoms, quality of life, and healthcare use. This study is not yet recruiting, and it aims to find better ways to help people living with these linked breathing conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female, 18 years of age or older;
• • With a diagnosis of asthma;
• • With a diagnosis of chronic rhinosinusitis with nasal polyposis;
• • Whose asthma and/or chronic rhinosinusitis is/are not controlled according to SNOT-22 and ACQ-6 scores;
• • Having used systemic corticosteroids in the previous year to treat symptoms related to one of these conditions at least;
• Exclusion Criteria:
• • Patient in a period of exclusion from another research protocol at the time of consent signature;
• • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (adult patients under guardianship or curatorship, patients deprived of their liberty, pregnant or breast-feeding women);
• • Patients who do not read and/or understand French